Compare · DERM vs VRCA

DERM vs VRCA

Side-by-side comparison of Journey Medical Corporation (DERM) and Verrica Pharmaceuticals Inc. (VRCA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DERM and VRCA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • DERM is the larger of the two at $104.2M, about 2.1x VRCA ($49.1M).
  • VRCA has been more active in the news (7 items in the past 4 weeks vs 4 for DERM).
  • VRCA has more recent analyst coverage (13 ratings vs 7 for DERM).
MetricDERMVRCA
Company
Journey Medical Corporation
Verrica Pharmaceuticals Inc.
Price
-
-
Market cap
$104.2M
$49.1M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2021
2018
News (4w)
4
7
Recent ratings
7
13
DERM

Journey Medical Corporation

Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

VRCA

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Latest DERM

Latest VRCA